Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nine-valent human papillomavirus vaccine: implications for cervical elimination.

The Lancet. Infectious diseases·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

Rechristen 'Cardiovascular-Kidney-Metabolic (CKM)' health to 'Cardiovascular-Kidney-Liver-Metabolic (CKLM)' health: Bridge the Gap.

Journal of clinical and experimental hepatology·2026
Same author

Sudomotor Dysfunction in Fibrocalculous Pancreatic Diabetes: Clinical Insights From Electrochemical Skin Conductance Testing.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

MASH associated lipotoxicity perturbs the expression of hepatic vitamin D bioactivating gene CYP2R1 in humans and mice.

Biochemical and biophysical research communications·2026
Same author

Nor-ursodeoxycholic Acid for Metabolic Dysfunction-associated Steatotic Liver Disease: Is There Enough Evidence for Clinical Use? A Critique of a Phase III Trial and Regulatory Endorsement of the Drug.

Journal of clinical and experimental hepatology·2026
Same journal

Applications of lupeol to manage fungal infections: a promising multi-target molecule.

Future microbiology·2026
Same journal

Benzyl isothiocyanate-loaded chitosan beads: a novel strategy to combat biofilm formation by <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>.

Future microbiology·2026
Same journal

<i>Mycobacterium colombiense</i> isolation among people living with human immunodeficiency virus: a case series.

Future microbiology·2026
Same journal

Thwarting the biothreat in the 21st century: means and methods.

Future microbiology·2026
Same journal

The oral-respiratory interface: modulation of <i>Streptococcus pneumoniae</i> serotype adhesion by the periodontal pathogen <i>Porphyromonas gingivalis</i> W83.

Future microbiology·2026
Same journal

Global One Health genomics identify conserved virulence and mobile resistance in the opportunistic pathogen <i>Staphylococcus saprophyticus</i>.

Future microbiology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Prevention of hepatitis E: another step forward.

Amit Goel1, Rakesh Aggarwal

  • 1Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.

Future Microbiology
|December 18, 2010
PubMed
Summary
This summary is machine-generated.

A new Hepatitis E vaccine proved safe and effective in a large trial. This vaccine protects against multiple Hepatitis E virus genotypes, offering a significant advancement in disease prevention.

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Related Experiment Videos

Last Updated: Jun 5, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Area of Science:

  • Hepatology
  • Virology
  • Vaccinology

Background:

  • Hepatitis E virus (HEV) causes acute viral hepatitis, often self-limiting but can lead to fatal fulminant hepatic failure, especially in pregnant women.
  • Current prevention strategies are limited, and existing vaccines are not widely available.
  • HEV infection is a significant public health concern, particularly in developing nations.

Discussion:

  • Zhu et al. conducted a large field trial of a novel HEV vaccine.
  • The vaccine contains a shorter viral capsid protein produced in Escherichia coli and adsorbed on alum.
  • The trial evaluated vaccine safety and efficacy in a diverse population aged 18-65.

Key Insights:

  • The evaluated vaccine demonstrated high safety and efficacy in preventing clinical Hepatitis E.
  • Protection was observed against HEV genotypes from which the vaccine was derived and other genotypes.
  • This represents a significant step forward in controlling HEV infections.

Outlook:

  • The successful trial suggests this vaccine could become a crucial tool in combating Hepatitis E globally.
  • Further research may explore broader genotype coverage and long-term efficacy.
  • Wider availability of effective vaccines can reduce the burden of HEV-related liver disease.